SavedAdd your journal

Journals / Turkish Journal of Chemistry / 2019 / Cilt: 43 - Sayı: 1

An insight into the therapeutic potential of piperazine-based anticancer agents

Matloob AHMAD
Kamran WALAYAT
Sana ASLAM
Noor-ul-Amin MOHSIN
Pages
1–23
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this article is to highlight the structural parameters imparting anticancer activity topiperazine derivatives and to indicate future perspectives for the discovery of new anticancer agents.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The piperazine ring system is among the medicinally important nitrogen-containing heterocyclic ring systemsand is exploited for the synthesis of various drug molecules.
📊
Key Findings & Data:In recent decades there has been an alarming increase in the number of people suffering fromcancerous diseases all over the world, which resulted in an extraordinary increase in research reports on new anticancerdrug candidates.
💡
Conclusion & Impact:The aim of this article is to highlight the structural parameters imparting anticancer activity topiperazine derivatives and to indicate future perspectives for the discovery of new anticancer agents.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The piperazine ring system is among the medicinally important nitrogen-containing heterocyclic ring systemsand is exploited for the synthesis of various drug molecules. A number of FDA-approved anticancer drugs containpiperazine rings and thus it is considered as an attractive scaffold having extraordinary potential for the developmentof new anticancer agents. In recent decades there has been an alarming increase in the number of people suffering fromcancerous diseases all over the world, which resulted in an extraordinary increase in research reports on new anticancerdrug candidates. The aim of this article is to highlight the structural parameters imparting anticancer activity topiperazine derivatives and to indicate future perspectives for the discovery of new anticancer agents.

🔖

Cite This Article

AHMAD, M., WALAYAT, K., ASLAM, S., MOHSIN, N. (2022). An insight into the therapeutic potential of piperazine-based anticancer agents. Turkish Journal of Chemistry, Cilt: 43 - Sayı: 1, 1–23. https://ajindex.com/articles/601650

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (25)

  1. Mareel, M.; Leroy, A. Physiol. Rev.2003, 83, 337-376
  2. Varmus, H. Science 2006, 312, 1162-1165
  3. Siegel, R. L.; Miller, K. D.; Jemal, A. CA-Cancer J. Clin. 2016, 66, 7-30
  4. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. CA-Cancer J. Clin. 2011, 61, 69-90
  5. Bray, F.; Jemal, A.; Grey, N.; Ferlay, J.; Forman, D. Lancet Oncol. 2012, 13, 790-801
  6. Atkins, J. H.; Gershell, L. J. Nat. Rev. Cancer.2002, 2, 645-646
  7. Jimeno, A.; Hidalgo, M. Crit. Rev. Oncol. Hemat. 2006, 59, 150-158
  8. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Nat. Rev. Drug Discov. 2006, 5, 219-234
  9. Khalili, F.; Henni, A.; East, A. L. J. Chem. Eng. Data 2009, 54, 2914-2917
  10. Khalaj, A.; Adibpour, N.; Shahverdi, A. R.; Daneshtalab, M. Eur. J. Med. Chem. 2004, 39, 699-705
  11. Upadhayaya, R. S.; Sinha, N.; Jain, S.; Kishore, N.; Chandra, R.; Arora, S. K. Bioorgan. Med. Chem.2004, 12, 2225-2238
  12. Chaudhary, P.; Kumar, R.; Verma, A. K.; Singh, D.; Yadav, V.; Chhillar, A. K.; Sharma, G.; Chandra, R. Bioorgan. Med. Chem.2006, 14, 1819-1826
  13. Broekkamp, C.; Leysen, D.; Peeters, B.; Pinder, R. J. Med. Chem. 1995, 38, 4615-4633
  14. Naito, H.; Ohsuki, S.; Atsumi, R.; Minami, M.; Mochizuki, M.; Hirotani, K.; Kumazawa, E.; Ejima, A. Chem. Pharm. Bull.2005, 53, 153-163
  15. Ibarra, M.; Hong, E.; Villalobos-Molina, R. J. Auton. Pharmacol. 2000, 20, 139-145
  16. Yoon, J.; Yoo, E. A.; Kim, J. Y.; Pae, A. N.; Rhim, H.; Park, W. K.; Kong, J. Y.; Choo, H. Y. P. Bioorgan. Med. Chem.2008, 16, 5405-5412
  17. Tollefson, G.; Lancaster, S.; Montague-Clouse, J. Psychopharmacol. Bull. 1991, 27, 163-170
  18. Rotzinger, S.; Fang, J.; Baker, G. B. Drug Metab. Dispos. 1998, 26, 572-575
  19. Rathi, A. K.; Syed, R.; Shin, H. S.; Patel, R. V. Expert Opin. Ther. Pat. 2016, 26, 777-797
  20. Tridente, G. Adverse Events and Oncotargeted Kinase Inhibitors; Academic Press: Cambridge, MA, USA, 2017
  21. Hamilton, E.; Infante, J. R. Cancer Treat. Rev. 2016, 45, 129-138
  22. Boschelli, F.; Arndt, K.; Gambacorti-Passerini, C. Eur. J. Cancer 2010, 46, 1781-1789
  23. Rosell, R.; Gettinger, S. N.; Bazhenova, L. A.; Langer, C. J.; Salgia, R.; Shaw, A. T.; Narasimhan, N. I.; Dorer, D. J.; Kerstein, D.; Camidge, D. R. J. Thorac. Oncol. 2016, 11, S113-S142
  24. Bates, M.; Lieu, D.; Zagari, M.; Spiers, A.; Williamson, T. Clin. Ther. 1997, 19, 167-184
  25. Cortes, J.; Rousselot, P.; Kim, D. W.; Ritchie, E.; Hamerschlak, N.; Coutre, S.; Hochhaus, A.; Guilhot,